Cancer Family
Adnexal Neoplasm
CI-CAN-00000005Explore in graph →
Non-malignant776 active trials5 approved drugs94 evidence items
- NCIt
- C212119
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000005Explore in graph →
Clinical trials
3,521 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07171528 | Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer(KOV-02S) | recruiting | Phase 2 | 80 | National Cancer Center, KoreaOTHER_GOV | 1 | Sep 12, 2025 | clinicaltrials |
| NCT05998135 | Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer | recruiting | Phase 2 | 28 | Emory UniversityOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05009082 | Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer | recruiting | Phase 3 | 970 | AGO Study GroupOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT07156253 | Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 110 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07152041 | Newly-diagnosed Pediatric Ph-positive B-ALL Protocol(CAMS-Ph+ B-ALL) | recruiting | Phase 3 | 150 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 2 | Sep 3, 2025 | clinicaltrials |
| NCT03878849 | Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer | recruiting | Phase 2 | 40 | Allarity TherapeuticsINDUSTRY | 1 | Aug 28, 2025 | clinicaltrials |
| NCT05113368 | Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer | recruiting | Phase 2 | 31 | Sarah K. Lynam MDOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT06508307 | A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors | recruiting | Phase 1 | 21 | GONGCHU Biotechnology Co., LtdOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT07021495 | SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)(SKINERGY) | recruiting | — | 840 | Leiden University Medical CenterOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT04429542 | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | recruiting | Phase 1 | 292 | Bicara TherapeuticsINDUSTRY | 3 | Aug 15, 2025 | clinicaltrials |
| NCT06976892 | Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer(IDOL) | recruiting | Phase 1 | 33 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT07100288 | Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian Cancer(INFPELV) | recruiting | — | 200 | Complejo Hospitalario Universitario Insular Materno InfantilOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06666270 | Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 30 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06019923 | Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer | recruiting | — | 100 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT07067255 | Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer(BAH2573-104) | recruiting | Phase 1 / Phase 2 | 80 | Essen BiotechOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07069335 | A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer | recruiting | Phase 1 | 24 | Boryung Pharmaceutical Co., LtdINDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06839144 | Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression(OC-POP-PT) | recruiting | Phase 2 | 60 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jul 11, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT07022535 | Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer(PRESELECT-0) | recruiting | Phase 2 | 18 | The University of Hong KongOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07023484 | Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer(Preselect-1) | recruiting | Phase 2 | 126 | The University of Hong KongOTHER | 2 | Jul 2, 2025 | clinicaltrials |
| NCT07039331 | Short-term Fasting Compared to Free Diet on Ovarian Cancer Patients(DIETA) | recruiting | N/A | 54 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT05796973 | Measuring Oncological Value of Exercise and Statin(MOVES) | recruiting | Phase 3 | 240 | Tampere University HospitalOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06817174 | Ovarian Cancer Radiomics Approach in CT Led Evaluation(ORACLE) | recruiting | — | 168 | Imperial College Healthcare NHS TrustOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT07035587 | Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques | recruiting | — | 1,200 | Yonsei UniversityOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT06769425 | HS-10502 Combination Treatment in Patients With Advanced Solid Tumors(HS-10502) | recruiting | Phase 1 | 157 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06954584 | Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer | recruiting | Phase 3 | 424 | Tongji HospitalOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT02288676 | DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics(DOvEEgene) | recruiting | — | 1,200 | McGill UniversityOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT06564428 | A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration | recruiting | — | 1,000 | Peking University Third HospitalOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT06292286 | Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer(SCENIC) | recruiting | N/A | 18 | The University of Hong KongOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT05740956 | A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 318 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT05518253 | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 30 | Weijia Fang, MDOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06988280 | Ultrasound-guided Transvaginal Aspiration of Cystic Pelvic Lesions(UTAC) | recruiting | — | 100 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06129968 | Transforming Ovarian Cancer Diagnostic Pathways(SONATA) | recruiting | — | 34,000 | Professor Sudha SundarOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT04503265 | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 122 | AtlasMedx, IncorporatedINDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT06686030 | Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer | recruiting | Phase 2 | 150 | AkesoINDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06907771 | Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer(PACO) | recruiting | — | 130 | University Hospital, Strasbourg, FranceOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06902467 | Combined Intraperitoneal Chemotherapy Regimen After Optimal Interval Surgery in Advanced Ovarian Cancer: BICOV-1 (Bidirectional Chemotherapy in Ovarian Cancer)(BICOV) | recruiting | N/A | 20 | Fundacion para la Formacion e Investigacion Sanitarias de la Region de MurciaOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06594679 | A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)(NICHOL) | recruiting | Phase 1 / Phase 2 | 73 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT06689605 | Ultrasound-guided Tru-cut Biopsy in Patients with Suspected Ovarian Cancer: Adequacy, Accuracy, Safety and Patient Assessment.(TRUCUTOC) | recruiting | — | 30 | University Hospital Hradec KraloveOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06883409 | Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer | recruiting | N/A | 33 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06890858 | A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer | recruiting | Phase 2 | 20 | Zhejiang Provincial People's HospitalOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT06324175 | Spatial Radiogenomics of Ovarian Cancer(CO-MOULD) | recruiting | — | 24 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT06331130 | Mesenteric Infiltration in Ovarian Cancer(MIO) | recruiting | — | 510 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06560112 | An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer | recruiting | Phase 2 | 172 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06635837 | Prospective Evaluation of the Role of MRI in Ovarian Masses During Pregnancy(PROM-P) | recruiting | — | 60 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT04196257 | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | recruiting | Phase 1 | 50 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06475261 | Tissue Oximetry's Measurement in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy | recruiting | — | 50 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT05704621 | Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance(SOCCER-P) | recruiting | Phase 2 | 124 | Korea University Guro HospitalOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT06085404 | Patients Derived Organoids in Ovarian Cancer(PICTURE) | recruiting | N/A | 48 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 4, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 12, 2025source: clinicaltrials